{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:48Z","timestamp":1787003628004,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Zhejiang Plan for the Special Support for Top-notch Talents","award":["2022R52029"],"award-info":[{"award-number":["2022R52029"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2022ZFJH003"],"award-info":[{"award-number":["2022ZFJH003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Key Research and Development Program in China","award":["2021YFC2301204"],"award-info":[{"award-number":["2021YFC2301204"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83026-x","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T03:38:55Z","timestamp":1735357135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021"],"prefix":"10.1038","volume":"14","author":[{"given":"Jia","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"83026_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/s1473-3099(16)00129-8","volume":"16","author":"EA Belongia","year":"2016","unstructured":"Belongia, E. A. et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect. Dis. 16, 942\u2013951. https:\/\/doi.org\/10.1016\/s1473-3099(16)00129-8 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"83026_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/cid\/cit060","volume":"56","author":"SE Ohmit","year":"2013","unstructured":"Ohmit, S. E. et al. Influenza vaccine effectiveness in the community and the household. Clin. Infect. Dis. 56, 1363\u20131369. https:\/\/doi.org\/10.1093\/cid\/cit060 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"83026_CR3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","volume":"14","author":"JS Tregoning","year":"2018","unstructured":"Tregoning, J. S., Russell, R. F. & Kinnear, E. Adjuvanted influenza vaccines. Hum. Vaccin. Immunother. 14, 550\u2013564. https:\/\/doi.org\/10.1080\/21645515.2017.1415684 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"83026_CR4","doi-asserted-by":"publisher","first-page":"1043109","DOI":"10.3389\/fimmu.2023.1043109","volume":"14","author":"SK Verma","year":"2023","unstructured":"Verma, S. K. et al. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 14, 1043109. https:\/\/doi.org\/10.3389\/fimmu.2023.1043109 (2023).","journal-title":"Front. Immunol."},{"key":"83026_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202004210","volume":"32","author":"S Peng","year":"2020","unstructured":"Peng, S. et al. Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant. Adv. Mater. 32, e2004210. https:\/\/doi.org\/10.1002\/adma.202004210 (2020).","journal-title":"Adv. Mater."},{"key":"83026_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., Arunachalam, P. S. & Oagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475. https:\/\/doi.org\/10.1038\/s41573-021-00163-y (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"83026_CR7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597\u20131608. https:\/\/doi.org\/10.1038\/nm.3409 (2013).","journal-title":"Nat. Med."},{"key":"83026_CR8","doi-asserted-by":"publisher","first-page":"1002286","DOI":"10.3389\/fimmu.2022.1002286","volume":"13","author":"ML Myers","year":"2022","unstructured":"Myers, M. L. et al. Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus. Front. Immunol. 13, 1002286. https:\/\/doi.org\/10.3389\/fimmu.2022.1002286 (2022).","journal-title":"Front. Immunol."},{"key":"83026_CR9","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","volume":"365","author":"T Vesikari","year":"2011","unstructured":"Vesikari, T. et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365, 1406\u20131416. https:\/\/doi.org\/10.1056\/NEJMoa1010331 (2011).","journal-title":"N. Engl. J. Med."},{"key":"83026_CR10","doi-asserted-by":"publisher","first-page":"11460","DOI":"10.1038\/s41598-018-29858-w","volume":"8","author":"YJ Lin","year":"2018","unstructured":"Lin, Y. J., Shih, Y. J., Chen, C. H. & Fang, C. T. Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis. Sci. Rep. 8, 11460. https:\/\/doi.org\/10.1038\/s41598-018-29858-w (2018).","journal-title":"Sci. Rep."},{"key":"83026_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1086\/592172","volume":"198","author":"WA Keitel","year":"2008","unstructured":"Keitel, W. A. et al. Safety and immunogenicity of an inactivated influenza A\/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J. Infect. Dis. 198, 1309\u20131316. https:\/\/doi.org\/10.1086\/592172 (2008).","journal-title":"J. Infect. Dis."},{"key":"83026_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1086\/527489","volume":"197","author":"DI Bernstein","year":"2008","unstructured":"Bernstein, D. I. et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197, 667\u2013675. https:\/\/doi.org\/10.1086\/527489 (2008).","journal-title":"J. Infect. Dis."},{"key":"83026_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/INF.0000000000000465","volume":"34","author":"L Zedda","year":"2015","unstructured":"Zedda, L. et al. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age. Pediatr. Infect. Dis. J. 34, 73\u201378. https:\/\/doi.org\/10.1097\/INF.0000000000000465 (2015).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"83026_CR14","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1016\/j.vaccine.2009.02.004","volume":"27","author":"T Vesikari","year":"2009","unstructured":"Vesikari, T., Groth, N., Karvonen, A., Borkowski, A. & Pellegrini, M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27, 6291\u20136295. https:\/\/doi.org\/10.1016\/j.vaccine.2009.02.004 (2009).","journal-title":"Vaccine"},{"key":"83026_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/s1473-3099(22)00024-x","volume":"22","author":"N Folschweiller","year":"2022","unstructured":"Folschweiller, N. et al. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1\u20132 randomised controlled trial. Lancet Infect. Dis. 22, 1062\u20131075. https:\/\/doi.org\/10.1016\/s1473-3099(22)00024-x (2022).","journal-title":"Lancet Infect. Dis."},{"key":"83026_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac983","author":"PL Winokur","year":"2023","unstructured":"Winokur, P. L. et al. Safety and Immunogenicity of a monovalent inactivated influenza A\/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciac983 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"83026_CR17","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1056\/NEJMoa0908535","volume":"361","author":"FC Zhu","year":"2009","unstructured":"Zhu, F. C. et al. A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med. 361, 2414\u20132423. https:\/\/doi.org\/10.1056\/NEJMoa0908535 (2009).","journal-title":"N. Engl. J. Med."},{"key":"83026_CR18","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1097\/INF.0b013e318257644f","volume":"31","author":"SL Block","year":"2012","unstructured":"Block, S. L. et al. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A\/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. Pediatr. Infect. Dis. J. 31, e92-98. https:\/\/doi.org\/10.1097\/INF.0b013e318257644f (2012).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"83026_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2165\/00063030-200822050-00001","volume":"22","author":"NJ Carter","year":"2008","unstructured":"Carter, N. J. & Plosker, G. L. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 22, 279\u2013292. https:\/\/doi.org\/10.2165\/00063030-200822050-00001 (2008).","journal-title":"BioDrugs"},{"key":"83026_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/infdis\/jiu173","volume":"210","author":"T Nolan","year":"2014","unstructured":"Nolan, T. et al. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J. Infect. Dis. 210, 545\u2013557. https:\/\/doi.org\/10.1093\/infdis\/jiu173 (2014).","journal-title":"J. Infect. Dis."},{"key":"83026_CR21","doi-asserted-by":"publisher","first-page":"2290345","DOI":"10.1080\/21645515.2023.2290345","volume":"19","author":"L Henning","year":"2023","unstructured":"Henning, L. et al. Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax. Hum. Vaccin. Immunother. 19, 2290345. https:\/\/doi.org\/10.1080\/21645515.2023.2290345 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"83026_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","volume":"36","author":"S Jackson","year":"2018","unstructured":"Jackson, S. et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 36, 668\u2013674. https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.038 (2018).","journal-title":"Vaccine"},{"key":"83026_CR23","doi-asserted-by":"publisher","first-page":"2249130","DOI":"10.1080\/22221751.2023.2249130","volume":"12","author":"TT Tzeng","year":"2023","unstructured":"Tzeng, T. T. et al. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine. Emerg. Microbes Infect. 12, 2249130. https:\/\/doi.org\/10.1080\/22221751.2023.2249130 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"83026_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111894","author":"X Kang","year":"2022","unstructured":"Kang, X., Li, Y., Zhao, Y. & Chen, X. Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines10111894 (2022).","journal-title":"Vaccines (Basel)"},{"key":"83026_CR25","unstructured":"Wang, L. G. CpG oligonucleotides and their applications. China patent CN 117568339 A (2024)."},{"key":"83026_CR26","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.antiviral.2024.105954","volume":"229","author":"J Ji","year":"2024","unstructured":"Ji, J. et al. Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant. Antivir. Res. 229, 105954. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105954 (2024).","journal-title":"Antivir. Res."},{"key":"83026_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1586\/erv.10.144","volume":"9","author":"Z Zakay-Rones","year":"2010","unstructured":"Zakay-Rones, Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev. Vaccines 9, 1423\u20131439. https:\/\/doi.org\/10.1586\/erv.10.144 (2010).","journal-title":"Expert Rev. Vaccines"},{"key":"83026_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2288-10-18","volume":"10","author":"L Coudeville","year":"2010","unstructured":"Coudeville, L. et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 10, 18. https:\/\/doi.org\/10.1186\/1471-2288-10-18 (2010).","journal-title":"BMC Med. Res. Methodol."},{"key":"83026_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41541-022-00486-w","volume":"7","author":"S Strohmeier","year":"2022","unstructured":"Strohmeier, S. et al. A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. NPJ Vaccines 7, 81. https:\/\/doi.org\/10.1038\/s41541-022-00486-w (2022).","journal-title":"NPJ Vaccines"},{"key":"83026_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","volume":"2197","author":"N Kayraklioglu","year":"2021","unstructured":"Kayraklioglu, N., Horuluoglu, B. & Klinman, D. M. CpG Oligonucleotides as Vaccine Adjuvants. Methods Mol. Biol. 2197, 51\u201385. https:\/\/doi.org\/10.1007\/978-1-0716-0872-2_4 (2021).","journal-title":"Methods Mol. Biol."},{"key":"83026_CR31","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1084\/jem.186.12.2063","volume":"186","author":"MB Graham","year":"1997","unstructured":"Graham, M. B. & Braciale, T. J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med. 186, 2063\u20132068. https:\/\/doi.org\/10.1084\/jem.186.12.2063 (1997).","journal-title":"J. Exp. Med."},{"key":"83026_CR32","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1099\/0022-1317-82-11-2697","volume":"82","author":"PP Heinen","year":"2001","unstructured":"Heinen, P. P., de Boer-Luijtze, E. A. & Bianchi, A. T. J. Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection. J. Gen. Virol. 82, 2697\u20132707. https:\/\/doi.org\/10.1099\/0022-1317-82-11-2697 (2001).","journal-title":"J. Gen. Virol."},{"key":"83026_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/14760584.2014.863715","volume":"13","author":"H Shirota","year":"2014","unstructured":"Shirota, H. & Klinman, D. M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev. Vaccines 13, 299\u2013312. https:\/\/doi.org\/10.1586\/14760584.2014.863715 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"83026_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nri1329","volume":"4","author":"DM Klinman","year":"2004","unstructured":"Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249\u2013258. https:\/\/doi.org\/10.1038\/nri1329 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"83026_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","volume":"20","author":"AM Krieg","year":"2002","unstructured":"Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709\u2013760. https:\/\/doi.org\/10.1146\/annurev.immunol.20.100301.064842 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"83026_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nrd2059","volume":"5","author":"AM Krieg","year":"2006","unstructured":"Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug. Discov. 5, 471\u2013484. https:\/\/doi.org\/10.1038\/nrd2059 (2006).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"83026_CR37","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ijbiomac.2021.11.020","volume":"193","author":"HT Lin","year":"2021","unstructured":"Lin, H. T. et al. Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. Int. J. Biol. Macromol. 193, 1885\u20131897. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.11.020 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"83026_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.virs.2022.06.002","volume":"37","author":"N Luan","year":"2022","unstructured":"Luan, N., Cao, H., Wang, Y., Lin, K. & Liu, C. LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix in VZV-primed mice. Virol. Sin. 37, 731\u2013739. https:\/\/doi.org\/10.1016\/j.virs.2022.06.002 (2022).","journal-title":"Virol. Sin."},{"key":"83026_CR39","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1002\/eji.200636483","volume":"37","author":"TA Barr","year":"2007","unstructured":"Barr, T. A., Brown, S., Ryan, G., Zhao, J. & Gray, D. TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur. J. Immunol. 37, 3040\u20133053. https:\/\/doi.org\/10.1002\/eji.200636483 (2007).","journal-title":"Eur. J. Immunol."},{"key":"83026_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020142","author":"M Luchner","year":"2021","unstructured":"Luchner, M., Reinke, S. & Milicic, A. TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics13020142 (2021).","journal-title":"Pharmaceutics"},{"key":"83026_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.addr.2008.12.008","volume":"61","author":"J Vollmer","year":"2009","unstructured":"Vollmer, J. & Krieg, A. M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug. Deliv. Rev. 61, 195\u2013204. https:\/\/doi.org\/10.1016\/j.addr.2008.12.008 (2009).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"83026_CR42","doi-asserted-by":"publisher","first-page":"eabj5305","DOI":"10.1126\/scitranslmed.abj5305","volume":"14","author":"E Nanishi","year":"2022","unstructured":"Nanishi, E. et al. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci. Transl. Med. 14, eabj5305. https:\/\/doi.org\/10.1126\/scitranslmed.abj5305 (2022).","journal-title":"Sci. Transl. Med."},{"key":"83026_CR43","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.4049\/jimmunol.0802257","volume":"182","author":"I Douagi","year":"2009","unstructured":"Douagi, I. et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J. Immunol. 182, 1991\u20132001. https:\/\/doi.org\/10.4049\/jimmunol.0802257 (2009).","journal-title":"J. Immunol."},{"key":"83026_CR44","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.2147\/dddt.S325790","volume":"15","author":"Q Li","year":"2021","unstructured":"Li, Q., Ren, J., Liu, W., Jiang, G. & Hu, R. CpG oligodeoxynucleotide developed to activate primate immune responses promotes antitumoral effects in combination with a neoantigen-based mRNA cancer vaccine. Drug. Des. Devel. Ther. 15, 3953\u20133963. https:\/\/doi.org\/10.2147\/dddt.S325790 (2021).","journal-title":"Drug. Des. Devel. Ther."},{"key":"83026_CR45","doi-asserted-by":"publisher","first-page":"2136912","DOI":"10.1080\/21645515.2022.2136912","volume":"18","author":"M Girndt","year":"2022","unstructured":"Girndt, M. et al. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B\u00ae) compared with HepB-Eng (Engerix-B\u00ae) and HepB-AS04 (Fendrix\u00ae) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study. Hum. Vaccin. Immunother. 18, 2136912. https:\/\/doi.org\/10.1080\/21645515.2022.2136912 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"83026_CR46","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.2022.2540","volume":"327","author":"K Bruxvoort","year":"2022","unstructured":"Bruxvoort, K. et al. Association between 2-dose vs 3-dose hepatitis b vaccine and acute myocardial infarction. Jama. 327, 1260\u20131268. https:\/\/doi.org\/10.1001\/jama.2022.2540 (2022).","journal-title":"Jama."},{"key":"83026_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9, C., Laup\u00e8ze, B., Del Giudice, G., Didierlaurent, A. M. & Tavares Da Silva, F. The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines 4, 39. https:\/\/doi.org\/10.1038\/s41541-019-0132-6 (2019).","journal-title":"NPJ Vaccines"},{"key":"83026_CR48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200678","author":"SA Vardhana","year":"2020","unstructured":"Vardhana, S. A. & Wolchok, J. D. The many faces of the anti-COVID immune response. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20200678 (2020).","journal-title":"J. Exp. Med."},{"key":"83026_CR49","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.4049\/jimmunol.164.11.5683","volume":"164","author":"BM Segal","year":"2000","unstructured":"Segal, B. M., Chang, J. T. & Shevach, E. M. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164, 5683\u20135688. https:\/\/doi.org\/10.4049\/jimmunol.164.11.5683 (2000).","journal-title":"J. Immunol."},{"key":"83026_CR50","doi-asserted-by":"publisher","first-page":"2202278","DOI":"10.1080\/22221751.2023.2202278","volume":"12","author":"N Ma","year":"2023","unstructured":"Ma, N. et al. Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence. Emerg. Microbes. Infect. 12, 2202278. https:\/\/doi.org\/10.1080\/22221751.2023.2202278 (2023).","journal-title":"Emerg. Microbes. Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83026-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83026-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83026-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T19:04:23Z","timestamp":1735412663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83026-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["83026"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83026-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CpG HP021 is patented by Jiangsu Taipurui Biotechnology Co., Ltd. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31424"}}